

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) An implantable article of manufacture for use in the release of a bioactive agent into a physiological environment, ~~said~~ the article comprising a matrix,

~~said the~~ matrix comprising

~~a biocompatible, bioerodable polymer,~~ a thermoplastic terpolymer selected from the group consisting of poly(lactide/glycolide/caprolactone) and poly(lactide/glycolide/valerolactone), the terpolymer having (i) an average molecular weight of 1,000 to 3,000, wherein the polymer has (ii) a water solubility of about 0.01 to about 500 mg/mL at about 25°C and (iii) an adhesive strength of about 600 to about 150,000 Pa so that the matrix is tissue adherent, and  
a bioactive agent.

2. (original) The article of claim 1 wherein the bioactive agent is a growth factor.

3. (canceled)

4. (new) The article of claim 2 wherein the growth factor is selected from the group consisting of a fibroblast growth factor, a transforming growth factor, a bone morphogenetic protein, an epidermal growth factor, a platelet-derived growth factor or an insulin-like growth factor.

5. (new) The article of claim 1 wherein the terpolymer has a glass transition temperature of less than 0°C.

6. (new) The article of claim 1 wherein the bioactive agent forms from about 10<sup>-5</sup>% to about 33% by weight of the matrix.

7. (new) The article of claim 6 wherein the terpolymer comprises about 35-45% lactide, about 35-45% glycolide, and about 10 to about 30% caprolactone.